Yet, clinical decision-making for BC treatment is still based on the evaluation of neoplastic cells, assessing hormone receptor (HR) expression and HER2 status, by immunohistochemistry and in situ hybridization (ISH) techniques, respectively [19]. This evidence concerns the gene HR and breast cancer.